NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer

Trial Profile

NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Durvalumab (Primary) ; MEDI 0562 (Primary) ; Oleclumab (Primary) ; Tremelimumab (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top